Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFSA 24: The EMBARK HFpEF Trial
Author(s): Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the… View more

Heart Failure
Vericiguat May Reduce Total Worsening HF Events
Added: 6 months ago Source:  Radcliffe Cardiology
An exploratory analysis of the VICTOR trial suggests that in compensated patients with heart failure and reduced ejection fraction (HFrEF), vericiguat may reduce the overall burden of worsening heart failure (HF) when outpatient events are included alongside hospitalisations.¹Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate pathway,… View more

Prevention & Chronic Conditions

Heart Failure
REBOOT-CNIC: Beta-Blockers Show No Benefit Post-MI in Patients with Preserved Ejection Fraction
Added: 9 months ago Source:  Radcliffe Cardiology
The long-standing practice of prescribing beta-blockers after a myocardial infarction (MI) has been re-examined in the contemporary era of reperfusion therapy. New findings from the REBOOT-CNIC trial suggest that for patients with a preserved left ventricular ejection fraction (LVEF), this routine therapy may not provide the expected benefits.¹REBOOT-CNIC was an open-label, randomised trial… View more

Imaging & Diagnostics

MI/ACS
POTCAST: Raising Potassium Levels Reduces Arrhythmia Risk in ICD Patients
Added: 9 months ago Source:  Arrhythmia Academy
A strategy of actively increasing plasma potassium to high-normal levels significantly lowered the risk of arrhythmia events in high-risk patients with an implantable cardioverter–defibrillator (ICD), according to results from the POTCAST trial.¹˒² The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England Journal of… View more

Electrophysiology & Arrhythmia

Heart Failure
Beta-Blockers Post-MI Show No Benefit in Preserved LVEF
Added: 4 months ago Source:  Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis… View more

MI/ACS

Heart Failure
Nothing to REFINE Yet
Author(s): Gheorghe-Andrei Dan Added: 7 months ago

Guidelines & Statements

Heart Failure
Lukla Biasi
Research Area(s) / Expertise:

Peripheral Artery Disease - General

 Job title: Consultant Vascular & Endovascular Surgeon
Dr Lukla Biasi is an experienced vascular and endovascular surgeon with a dedicated commitment to the sub-specialties of lower limb revascularisation and carotid surgery. Lukla Biasi graduated with distinguished honours from the University of Bologna, Italy; following a research fellowship at St Georges’ Vascular Institute in London, he completed the specialist training at the University… View more
Autophagy and Endoplasmic Reticulum Stress in HFpEF
Author(s): Citrawati Dyah Kencono Wungu , Hendri Susilo , Cleodylon Reinard Susanto , et al Added: 4 months ago

MI/ACS

Prevention & Chronic Conditions
Francis E Marchlinski
Research Area(s) / Expertise: Job title: Director of Electrophysiology Laboratory
Research Expertise Electrophysiology of the human atria and ventricles Mechanism of supraventricular and ventricular arrhythmias Anatomic and electrophysiologic substrate of atrial and ventricular arrhythmias. Catheter ablative therapy in atrial and ventricular arrhythmias Device therapy in management of ventricular arrhythmias Arrhythmogenic cardiomyopathy and cardiac arrhythmias … View more
DanGer Shock RCT: A Decade of Data
Author(s): Andreas Goetzenich, Jacob E Møller, Vasileios Panoulas ,et al Start date: Dec 02, 2025
Gain critical insights into how the landmark DanGer Shock RCT is reshaping cardiogenic shock management, improving patient outcomes and enhancing collaborative care strategies in real-world settings.In this webinar, leading experts and trial investigators Dr Jacob Møller (Copenhagen University Hospital, Copenhagen, DK), Dr Vasileios Panoulas (Harefield Hospital, London, UK), Prof Christian… View more

Intervention

MI/ACS